Health
LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials – News-Medical.Net
A new study, published in Nano Letters, describes an effective new COVID-19 vaccine candidate based on a messenger ribonucleic acid (mRNA) platform.
Even as over a score of vaccines against the coronavirus disease 2019 (COVID-19) pandemic have been rolled out following their emergence use authorization, others continue to be researched to fill the global need for effective deployment the world over.
A new study, published in Nano Letters, describes an effective new vaccine candidate based on a messenger ribonucleic acid (mRNA) platform.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attaches to host cells via its spike protein,…
-
Noosa News15 hours agoConsolidated Pastoral Company buys Beetaloo aggregation in historic deal worth more than $300m
-
General23 hours agoWotjobaluk Nations Festival marks landmark native title recognition
-
Business18 hours agoWhy are ASX 200 tech stocks like Xero shares taking a beating on Monday?
-
Noosa News20 hours agoEight New Year’s Eve Events in Brisbane 2026